<p>马萨诸塞州列克星敦 --（商业资讯）--Aldeyra Therapeutics, Inc.（纳斯达克代码：ALDX）（Aldeyra）是一家致力于发现和开发创新疗法以治疗免疫介导疾病的生物技术公司，今天宣布美国食品和药物管理局（FDA）已延长了针对干眼症治疗的 reproxalap 新药申请（NDA）的处方药用户费用法案（PDUFA）目标行动日期。延长后的 PDUFA 目标行动日期为 2026 年 3 月 16 日。</p>
<p>在 2025 年 6 月 16 日提交后，NDA 于 2025 年 7 月 16 日被 FDA 接受为 “完整的 2 类响应”，目标 PDUFA 行动日期为 2025 年 12 月 16 日。2025 年 12 月 12 日，FDA 与 Aldeyra 会面，要求提交 reproxalap 干眼症领域试验的临床研究报告（CSR）至 NDA，顶线结果于 2025 年 5 月 5 日公布。该领域试验支持 reproxalap 相对于对照组的活性，但未达到相对于对照组改善干眼症状的主要终点。在 2025 年 6 月提交 NDA 之前，该领域试验已与 FDA 进行了讨论。</p>
<p>在 12 月 12 日的会议上，FDA 没有提出其他要求，也没有指出 NDA 审查中的其他具体问题。此前已提交至 reproxalap 研究性新药（IND）档案的 CSR 在会议当天提交至 NDA，并被 FDA 视为 NDA 的重大修正。根据 FDA 在 NDA 审查期间的早期要求，来自该领域试验的安全性数据于 2025 年 8 月 21 日提交至 NDA。CSR 已在 IND 下由 FDA 进行审查。</p>
<p>在 12 月初，FDA 与 Aldeyra 分享了潜在标签的草稿，Aldeyra 已提交了回应。FDA 通知 Aldeyra，如果在延长审查期间未发现重大缺陷，FDA 计划在 2026 年 2 月 16 日之前沟通拟议的标签请求，并在必要时提出任何预期的上市后要求。</p>
<p><strong>电话会议及网络直播信息</strong> Aldeyra 将在 2025 年 12 月 16 日（星期二）东部时间上午 8:00 召开电话会议，讨论 PDUFA 延期。拨入号码为国内拨打者（833）470-1428，国际拨打者（646）844-6383。访问代码为 438712。电话会议的实时网络直播将在公司网站的投资者关系页面上提供，网址为 https://ir.aldeyra.com。直播结束后，该活动将在 Aldeyra Therapeutics 网站上存档 90 天。</p>
<p><strong>关于 Aldeyra</strong> Aldeyra Therapeutics 是一家致力于发现创新疗法以治疗免疫介导疾病的生物技术公司。我们的做法是开发调节蛋白系统的药物，而不是直接抑制或激活单一蛋白靶点，目标是同时优化多个通路，同时最小化毒性。我们的产品候选包括 RASP（反应性醛类物质）调节剂 ADX-248、ADX-246 及其化学相关分子，潜在用于治疗全身性和视网膜免疫介导疾病。我们的后期产品候选包括 reproxalap，一种用于潜在治疗干眼症和过敏性结膜炎的 RASP 调节剂，以及 ADX-2191，一种新型的玻璃体内甲氨蝶呤制剂，潜在用于治疗原发性玻璃体视网膜淋巴瘤和色素性视网膜炎。</p>
<p><em><strong>安全港声明</strong></em> 本发布包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明，包括但不限于关于 Aldeyra 未来期望、计划和前景的声明，包括但不限于：预期的监管行动时间；reproxalap 治疗干眼症的新药申请的结果，包括如果获得批准，reproxalap 的标签；以及 reproxalap 的目标、机会和商业潜力。Aldeyra 意图将此类前瞻性声明纳入 1934 年《证券交易法》第 21E 节和 1995 年《私人证券诉讼改革法案》中的安全港条款。在某些情况下，您可以通过诸如 “可能”、“或许”、“将”、“目标”、“打算”、“应该”、“可以”、“会”、“期望”、“相信”、“预期”、“项目”、“按计划”、“安排”、“目标”、“设计”、“估计”、“预测”、“考虑”、“可能”、“潜在”、“继续”、“正在进行”、“旨在”、“计划” 或这些术语的否定形式，以及类似的表达来识别前瞻性声明。这些前瞻性声明基于当前的期望，涉及风险、情况变化、假设和不确定性。Aldeyra 处于开发的早期阶段，可能永远不会有任何能够产生显著收入的产品。Aldeyra 的所有开发时间表可能会根据招募速度、监管审查、临床前和临床结果、资金以及其他可能延迟临床试验启动、招募或完成的因素进行调整。可能导致实际结果与 Aldeyra 的前瞻性声明显著不同的重要因素包括但不限于：Aldeyra 临床试验的招募、开始和完成的时间；Aldeyra 及其开发合作伙伴进行的临床前研究和临床试验的时间和成功；延迟或未能获得 Aldeyra 产品候选者的监管批准，包括由于 FDA 未接受 Aldeyra 的监管申请、发出完整回复信，或在审查或批准此类申请或与此类申请的重新提交相关时要求额外的临床试验或数据；维持 Aldeyra 产品候选者的监管批准及任何已批准产品的标签的能力；先前结果的风险，例如在临床前或临床试验中观察到的安全性、活性或效果持久性的信号，可能不会在涉及 Aldeyra 产品候选者的正在进行或未来的研究或临床试验中复制或持续；开发和商业化 Aldeyra 产品候选者的范围、进展、扩展和成本；对 Aldeyra 在获得监管批准后（如有）单独或与他人共同商业化及获得报销的能力的不确定性；Aldeyra 产品候选者的潜在市场规模和增长及其服务这些市场的能力；Aldeyra 对其支出和未来收入的预期、未来收入的时间、Aldeyra 现金资源的充足性或使用及对额外融资的需求；Aldeyra 任何产品候选者的市场接受率的速度和程度；Aldeyra 对竞争的预期；Aldeyra 预期的增长战略；Aldeyra 吸引或留住关键人员的能力；Aldeyra 的商业化、营销和制造能力及战略；Aldeyra 建立和维持开发合作伙伴关系的能力；Aldeyra 成功将收购整合到其业务中的能力；Aldeyra 对联邦、州和外国监管要求的预期；可能影响 Aldeyra 业务或全球经济的政治、经济、法律、社会和健康风险、公共卫生措施以及战争或其他军事行动；美国和外国的监管发展；Aldeyra 获得和维持其产品候选者的知识产权保护的能力；Aldeyra 业务及其运营市场的预期趋势和挑战；以及在 Aldeyra 截至 2024 年 12 月 31 日的年度报告的 “风险因素” 和 “管理层对财务状况和经营成果的讨论与分析” 部分以及 Aldeyra 截至 2025 年 9 月 30 日的季度报告中描述的其他因素，这些报告已提交给证券交易委员会（SEC）并可在 SEC 网站上获取 https://www.sec.gov/。除了上述风险和 Aldeyra 在 SEC 的其他文件中描述的风险外，其他未知或不可预测的因素也可能影响 Aldeyra 的结果。无法保证任何前瞻性声明，实际结果可能与此类声明显著不同。本发布中的信息仅在发布之日提供，Aldeyra 不承担因新信息、未来事件或其他原因更新本发布中包含的任何前瞻性声明的义务，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTUyOTM2NzdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTUyOTM2NzdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251215293677/en/</p>
<p><strong>投资者与媒体</strong></p>
<p>劳拉·尼科尔斯</p>
<p>(781) 257-3060</p>
<p>investorrelations@aldeyra.com</p>
<p>来源：Aldeyra Therapeutics, Inc.</p>

Aldeyra治疗

<p>Aldeyra Therapeutics 宣布，FDA 已将其药物 reproxalap（用于干眼症治疗）的 PDUFA 目标行动日期延长至 2026 年 3 月 16 日。此次延长是由于要求提供额外的临床研究数据。Aldeyra 将召开电话会议以讨论此次延长。如果没有发现重大缺陷，FDA 计划在 2026 年 2 月 16 日前沟通标签请求</p>

<p>LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026.</p>
<div class="lb-trans"><p>马萨诸塞州列克星敦 --（商业资讯）--Aldeyra Therapeutics, Inc.（纳斯达克代码：ALDX）（Aldeyra）是一家致力于发现和开发创新疗法以治疗免疫介导疾病的生物技术公司，今天宣布美国食品和药物管理局（FDA）已延长了针对干眼症治疗的 reproxalap 新药申请（NDA）的处方药用户费用法案（PDUFA）目标行动日期。延长后的 PDUFA 目标行动日期为 2026 年 3 月 16 日。</p>
</div><p>Following submission on June 16, 2025, the NDA was accepted for review as a “complete class 2 response” by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025. On December 12, 2025, the FDA met with Aldeyra to request submission to the NDA of the Clinical Study Report (CSR) for the dry eye disease field trial of reproxalap, for which top-line results were announced on May 5, 2025. The field trial, which was supportive of the activity of reproxalap relative to vehicle, did not meet the primary endpoint of improvement in dry eye symptoms relative to the vehicle control. Prior to submitting the NDA in June, the field trial was discussed with the FDA.</p>
<div class="lb-trans"><p>在 2025 年 6 月 16 日提交后，NDA 于 2025 年 7 月 16 日被 FDA 接受为 “完整的 2 类响应”，目标 PDUFA 行动日期为 2025 年 12 月 16 日。2025 年 12 月 12 日，FDA 与 Aldeyra 会面，要求提交 reproxalap 干眼症领域试验的临床研究报告（CSR）至 NDA，顶线结果于 2025 年 5 月 5 日公布。该领域试验支持 reproxalap 相对于对照组的活性，但未达到相对于对照组改善干眼症状的主要终点。在 2025 年 6 月提交 NDA 之前，该领域试验已与 FDA 进行了讨论。</p>
</div><p>At the December 12 meeting, the FDA made no other requests and did not identify any other specific issues with the NDA review. The CSR, which had been previously submitted to the Investigational New Drug (IND) file for reproxalap, was submitted to the NDA the same day of the meeting and was considered a major amendment to the NDA by the FDA. Per the FDA’s earlier request during the NDA review, the safety data from the field trial was submitted to the NDA on August 21, 2025. The CSR has been reviewed by the FDA under the IND.</p>
<div class="lb-trans"><p>在 12 月 12 日的会议上，FDA 没有提出其他要求，也没有指出 NDA 审查中的其他具体问题。此前已提交至 reproxalap 研究性新药（IND）档案的 CSR 在会议当天提交至 NDA，并被 FDA 视为 NDA 的重大修正。根据 FDA 在 NDA 审查期间的早期要求，来自该领域试验的安全性数据于 2025 年 8 月 21 日提交至 NDA。CSR 已在 IND 下由 FDA 进行审查。</p>
</div><p>In early December, the FDA shared with Aldeyra a draft of the prospective label, and Aldeyra has submitted a response. The FDA notified Aldeyra that if no major deficiencies are identified during the extended review, the FDA plans to communicate proposed labeling requests and, if necessary, any anticipated postmarketing requirements by February 16, 2026.</p>
<div class="lb-trans"><p>在 12 月初，FDA 与 Aldeyra 分享了潜在标签的草稿，Aldeyra 已提交了回应。FDA 通知 Aldeyra，如果在延长审查期间未发现重大缺陷，FDA 计划在 2026 年 2 月 16 日之前沟通拟议的标签请求，并在必要时提出任何预期的上市后要求。</p>
</div><p><strong>Conference Call &amp; Webcast Information</strong> Aldeyra will host a conference call at 8:00 a.m. ET tomorrow, Tuesday December 16, 2025, to discuss the PDUFA extension. The dial-in numbers are (833) 470-1428 for domestic callers and (646) 844-6383 for international callers. The access code is 438712. A live webcast of the conference call will be available on the Investor Relations page of the company's website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.</p>
<div class="lb-trans"><p><strong>电话会议及网络直播信息</strong> Aldeyra 将在 2025 年 12 月 16 日（星期二）东部时间上午 8:00 召开电话会议，讨论 PDUFA 延期。拨入号码为国内拨打者（833）470-1428，国际拨打者（646）844-6383。访问代码为 438712。电话会议的实时网络直播将在公司网站的投资者关系页面上提供，网址为 https://ir.aldeyra.com。直播结束后，该活动将在 Aldeyra Therapeutics 网站上存档 90 天。</p>
</div><p><strong>About Aldeyra</strong> Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.</p>
<div class="lb-trans"><p><strong>关于 Aldeyra</strong> Aldeyra Therapeutics 是一家致力于发现创新疗法以治疗免疫介导疾病的生物技术公司。我们的做法是开发调节蛋白系统的药物，而不是直接抑制或激活单一蛋白靶点，目标是同时优化多个通路，同时最小化毒性。我们的产品候选包括 RASP（反应性醛类物质）调节剂 ADX-248、ADX-246 及其化学相关分子，潜在用于治疗全身性和视网膜免疫介导疾病。我们的后期产品候选包括 reproxalap，一种用于潜在治疗干眼症和过敏性结膜炎的 RASP 调节剂，以及 ADX-2191，一种新型的玻璃体内甲氨蝶呤制剂，潜在用于治疗原发性玻璃体视网膜淋巴瘤和色素性视网膜炎。</p>
</div><p><em><strong>Safe Harbor Statement</strong></em> This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: anticipated timing of regulatory action; the outcome of the New Drug Application of reproxalap for the treatment of dry eye disease, including, if approved, the label for reproxalap; and the goals, opportunity, and commercial potential for reproxalap. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” &#34;could,&#34; “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “on track,” “scheduled,” “target,” “design,” “estimate,” “predict,” “contemplates,” “likely,” “potential,” “continue,” “ongoing,” “aim,” “plan,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra’s regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra’s ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra’s commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra’s ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra’s business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2024, and Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC website at https://www.sec.gov/. In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.</p>
<div class="lb-trans"><p><em><strong>安全港声明</strong></em> 本发布包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明，包括但不限于关于 Aldeyra 未来期望、计划和前景的声明，包括但不限于：预期的监管行动时间；reproxalap 治疗干眼症的新药申请的结果，包括如果获得批准，reproxalap 的标签；以及 reproxalap 的目标、机会和商业潜力。Aldeyra 意图将此类前瞻性声明纳入 1934 年《证券交易法》第 21E 节和 1995 年《私人证券诉讼改革法案》中的安全港条款。在某些情况下，您可以通过诸如 “可能”、“或许”、“将”、“目标”、“打算”、“应该”、“可以”、“会”、“期望”、“相信”、“预期”、“项目”、“按计划”、“安排”、“目标”、“设计”、“估计”、“预测”、“考虑”、“可能”、“潜在”、“继续”、“正在进行”、“旨在”、“计划” 或这些术语的否定形式，以及类似的表达来识别前瞻性声明。这些前瞻性声明基于当前的期望，涉及风险、情况变化、假设和不确定性。Aldeyra 处于开发的早期阶段，可能永远不会有任何能够产生显著收入的产品。Aldeyra 的所有开发时间表可能会根据招募速度、监管审查、临床前和临床结果、资金以及其他可能延迟临床试验启动、招募或完成的因素进行调整。可能导致实际结果与 Aldeyra 的前瞻性声明显著不同的重要因素包括但不限于：Aldeyra 临床试验的招募、开始和完成的时间；Aldeyra 及其开发合作伙伴进行的临床前研究和临床试验的时间和成功；延迟或未能获得 Aldeyra 产品候选者的监管批准，包括由于 FDA 未接受 Aldeyra 的监管申请、发出完整回复信，或在审查或批准此类申请或与此类申请的重新提交相关时要求额外的临床试验或数据；维持 Aldeyra 产品候选者的监管批准及任何已批准产品的标签的能力；先前结果的风险，例如在临床前或临床试验中观察到的安全性、活性或效果持久性的信号，可能不会在涉及 Aldeyra 产品候选者的正在进行或未来的研究或临床试验中复制或持续；开发和商业化 Aldeyra 产品候选者的范围、进展、扩展和成本；对 Aldeyra 在获得监管批准后（如有）单独或与他人共同商业化及获得报销的能力的不确定性；Aldeyra 产品候选者的潜在市场规模和增长及其服务这些市场的能力；Aldeyra 对其支出和未来收入的预期、未来收入的时间、Aldeyra 现金资源的充足性或使用及对额外融资的需求；Aldeyra 任何产品候选者的市场接受率的速度和程度；Aldeyra 对竞争的预期；Aldeyra 预期的增长战略；Aldeyra 吸引或留住关键人员的能力；Aldeyra 的商业化、营销和制造能力及战略；Aldeyra 建立和维持开发合作伙伴关系的能力；Aldeyra 成功将收购整合到其业务中的能力；Aldeyra 对联邦、州和外国监管要求的预期；可能影响 Aldeyra 业务或全球经济的政治、经济、法律、社会和健康风险、公共卫生措施以及战争或其他军事行动；美国和外国的监管发展；Aldeyra 获得和维持其产品候选者的知识产权保护的能力；Aldeyra 业务及其运营市场的预期趋势和挑战；以及在 Aldeyra 截至 2024 年 12 月 31 日的年度报告的 “风险因素” 和 “管理层对财务状况和经营成果的讨论与分析” 部分以及 Aldeyra 截至 2025 年 9 月 30 日的季度报告中描述的其他因素，这些报告已提交给证券交易委员会（SEC）并可在 SEC 网站上获取 https://www.sec.gov/。除了上述风险和 Aldeyra 在 SEC 的其他文件中描述的风险外，其他未知或不可预测的因素也可能影响 Aldeyra 的结果。无法保证任何前瞻性声明，实际结果可能与此类声明显著不同。本发布中的信息仅在发布之日提供，Aldeyra 不承担因新信息、未来事件或其他原因更新本发布中包含的任何前瞻性声明的义务，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTUyOTM2NzdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251215293677r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251215293677/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251215293677/en/</p>
</div><p><strong>Investor &amp; Media</strong></p>
<div class="lb-trans"><p><strong>投资者与媒体</strong></p>
</div><p>Laura Nichols</p>
<div class="lb-trans"><p>劳拉·尼科尔斯</p>
</div><p>(781) 257-3060</p>
<div class="lb-trans"><p>(781) 257-3060</p>
</div><p>investorrelations@aldeyra.com</p>
<div class="lb-trans"><p>investorrelations@aldeyra.com</p>
</div><p>Source: Aldeyra Therapeutics, Inc.</p>
<div class="lb-trans"><p>来源：Aldeyra Therapeutics, Inc.</p>
</div>

Aldeyra 治疗公司宣布 Reproxalap 用于治疗干眼症的新药申请的 PDUFA 日期延期 | ALDX 股票新闻